



14<sup>Th</sup>, February, 2024

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai - 400001

Scrip Code: 524632

Dear Sir/Madam.

Sub: Statement of deviation or variation in the use of proceeds of Rights Issue Ref: Regulation 32 of SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015.

Pursuant to Regulation 32 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015, We hereby confirm that there is no deviation and/or variation in the utilization of proceeds, from the object mentioned in the letter of offer dated February 01, 2023 for Right Issue of partly paid-up equity shares and forfeiture cum demand notice dated October 13, 2023, for the payment of First Call Money of Rs. 07.00 per partly-up Equity Share (comprising Rs. 3.50 towards face value and Rs. 3.50 towards securities premium) and/or Second & Final Call Money of Rs. 8.00 per partly-up Equity Share (comprising Rs. 4.00 towards face value and Rs. 17,30,665 received upon such notice have been fully utilized for the quarter ended on December 31, 2023.

A statement of deviation, stating that there is no deviation or variation in the utilization of these proceeds, duly reviewed by the Audit Committee, is attached herewith as Annexure-A.

This is for your kind information and record.

Thanking You

Yours faithfully

For, Shukra Pharmaceuticals Limited

Bhoomi Patel

Director

DIN:0836893

Encl.: a/a

CIN: L24231GJ1993PLC019079





Statement of Deviation / Variation in utilization of funds raised under Right issue - Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Name of Listed Entity	Shukra Pharmaceuticals Limited		
Mode of Fund Raising	Right Issue of Partly Paid-Up Equity Shares		
Date of Raising Fund	October 16, 2023 (Being the demand notice Progression Date)		
Amount Raised	Rs. 0.17 Crore (Towards the first and /or second & final call money)  (Total amount raised under Rights issue is ₹ 18.59 Crores)		
Report filed for Quarter and Year Ended	December 31, 2023		
Monitoring Agency	NA		
Monitoring Agency Name, If Applicable	NA		
Is there any Deviation / Variation in use of funds raised	No		
If yes, Whether the same is pursuant to change in terms of a contract or object, which was approved by the shareholders	NA		
If Yes, Date of Shareholder approval	NA		
Explanation for Deviation / Variation	NA		
Comments of Audit Committee after review	No Comments		
Comments of auditors if any	No Comments		

CIN: L24231GJ1993PLC019079





Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	d Original Allocation	Modified allocation, if any	Funds Utilized	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Existing an incremental working capital requirement our company		Rs. 0.13 Crores	Nil	Rs. 0.13 Crores	Nil	No deviation
General Corporat Purposes	te Nil	Rs. 0.04 Crores	Nil	Rs. 0.04 Crores	Nil	No deviation

## Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fundraising document i.e., prospectus, letter of offer, etc

For, Shukra Pharmaceuticals Limited

AHMEDARAD

Bhoomi Patel Director

DIN:0836893

Date: 14/02/2024 Place: Ahmedabad

CIN: L24231GJ1993PLC019079